Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

ConclusionCompared to female patients, male patients had greater response rates in ACR20/50/70, MDA/VLDA, and DAPSA LDA/remission and numerically larger improvements in these measures ’ individual components, although clinical significance is unclear. Continued efforts to understand sex differences in treatment response may provide insights that can help optimize clinical decision making.Trial registrationClinicalTrials.gov identifiers, NCT01695239 and NCT02349295.

http://link.springer.com/10.1007/s40744-022-00445-w

Source: Rheumatology and Therapy - April 9, 2022 Category: Rheumatology Source Type: research